Oncolytic Herpes Viral Therapy is Effective in the Treatment of Hepatocellular Carcinoma Cell Lines

Journal of Gastrointestinal Surgery

Volumn 10, Issue 4, 2006, Pages 532-542

  Song, Tae Jin ^b   Eisenberg, David P ^b   Adusumilli, Prasad S ^b   Hezel, Michael ^b   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

G207; gene therapy; hepatocellular carcinoma; herpes simplex virus

Indexed keywords

EID: 33646040377     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gassur.2005.08.036     Document Type: Article

References (58)

1. Staib F., Hussain S.P., Hofseth L.J., Wang X.W., and Harris C.C. Tp53 and liver carcinogenesis. Hum Mutat 21 (2003) 201-216
2. Wang X.W., Hussain S.P., Huo T.I., et al. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 181-182 (2002) 43-47
3. Okuda K. Hepatocellular carcinoma. J Hepatol 32 (2000) 225-237
4. American Cancer Society. Cancer Statistics Presentation 2004 (2004), American Cancer Society. http://www.cancer.org/docroot/pro/content/pro_1_1_cancer_statistics_2004_presentation.asp Last accessed 14 Feb 2006
5. Toda M., Rabkin S.D., and Martuza R.L. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 9 (1998) 2177-2185
6. Todo T., Rabkin S.D., Chahlavi A., and Martuza R.L. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum Gene Ther 10 (1999) 2869-2878
7. Chahlavi A., Todo T., Martuza R.L., and Rabkin S.D. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1 (1999) 162-169
8. Coukos G., Makrigiannakis A., Montas S., et al. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther 7 (2000) 275-283
9. Oyama M., Ohigashi T., Hoshi M., et al. Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207. Hum Gene Ther 11 (2000) 1683-1693
10. Cozzi P., Burke P.B., Bhargava A., et al. Oncolytic viral gene therapy for prostate cancer using two attenuated, replication competent, genetically-engineered herpes simplex viruses. Prostate 53 (2002) 95-100
11. Stanziale S.F., and Fong Y. Novel approaches to cancer therapy using oncolytic viruses. Curr Mol Med 3 (2003) 61-71
12. Ebright M.I., Zager J.S., Malhotra S., et al. Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model. J Thorac Cardiovasc Surg 124 (2002) 123-129
13. Bennett J.J., Malhotra S., Wong R.J., et al. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann Surgery 233 (2001) 819-826
14. Bennett J.J., Kooby D.A., Delman K., et al. Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J Mol Med 78 (2000) 166-174
15. Carew J.F., Kooby D.A., Halterman M.W., Federoff H.J., and Fong Y. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum Gene Ther 10 (1999) 1599-1606
16. Cozzi P.J., Malhotra S., McAuliffe P., et al. Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and NV1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J 15 (2001) 1306-1308
17. Yazaki T., Manz H.J., Rabkin S.D., and Martuza R.L. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 55 (1995) 4752-4756
18. Mineta T., Rabkin S.D., Yazaki T., Hunter W.D., and Martuza R.L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1 (1995) 938-943
19. Chou J., Kern E.R., Whitley R.J., and Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 250 (1990) 1262-1266
20. Whitley R.J., Kern E.R., Chatterjee S., Chou J., and Roizman B. Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J Clin Invest 91 (1993) 2837-2843
21. Carroll N.M., Chiocca E.A., Takahashi K., and Tanabe K.K. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 224 (1996) 323-329
22. Goldstein D.J., and Weller S.K. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: Characterization of an ICP6 deletion mutant. Virology 166 (1988) 41-51
23. Goldstein D.J., and Weller S.K. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 62 (1988) 196-205
24. Decker T., and Lohmann-Matthes M.L. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 115 (1988) 61-69
25. Korzeniewski C., and Callewaert D.M. An enzyme-release assay for natural cytotoxicity. J Immunol Methods 64 (1983) 313-320
26. Weidmann E., Brieger J., Jahn B., Hoelzer D., Bergmann L., and Mitrou P.S. Lactate dehydrogenase-release assay: A reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia. Ann Hematol 70 (1995) 153-158
27. Park J.G., Lee S.K., Hong I.G., et al. MDR1 gene expression: Its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. J Natl Cancer Inst 86 (1994) 700-705
28. Fogh J., Fogh J.M., and Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59 (1977) 221-226
29. Kang M.S., Lee H.J., Lee J.H., et al. Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX DNA. Int J Cancer 67 (1996) 898-902
30. Kim S.O., Park J.G., and Lee Y.I. Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: Implications of IGF-I receptor gene activation by hepatitis B virus × gene product. Cancer Res 56 (1996) 3831-3836
31. Park J.G., Lee J.H., Kang M.S., et al. Characterization of cell lines established from human hepatocellular carcinoma. Int J Cancer 62 (1995) 276-282
32. Alexander J.J., Bey E.M., Geddes E.W., and Lecatsas G. Establishment of a continuously growing cell line from primary carcinoma of the liver. S Afr Med J 50 (1976) 2124-2228
33. Gilligan A., Bushmeyer S., and Knowles B.B. Variation in EGF-induced EGF receptor downregulation in human hepatoma-derived cell lines expressing different amounts of EGF receptor. Exp Cell Res 200 (1992) 235-241
34. Macnab G.M., Urbanowicz J.M., Geddes E.W., and Kew M.C. Hepatitis-B surface antigen and antibody in Bantu patients with primary hepatocellular cancer. Br J Cancer 33 (1976) 544-548
35. Kawai H.F., Kaneko S., Honda M., Shirota Y., and Kobayashi K. Alpha-fetoprotein-producing hepatoma cell lines share common expression profiles of genes in various categories demonstrated by cDNA microarray analysis. Hepatology 33 (2001) 676-691
36. Heffelfinger S.C., Hawkins H.H., Barrish J., Taylor L., and Darlington G.J. SK HEP-1: A human cell line of endothelial origin. In Vitro Cell Dev Biol 28A (1992) 136-142
37. Gucev Z.S., Oh Y., Kelley K.M., Labarta J.I., Vorwerk P., and Rosenfeld R.G. Evidence for insulin-like growth factor (IGF)-independent transcriptional regulation of IGF binding protein-3 by growth hormone in SKHEP-1 human hepatocarcinoma cells. Endocrinology 138 (1997) 1464-1470
38. Turner B.M., and Turner V.S. Secretion of alpha 1-antitrypsin by an established human hepatoma cell line and by human/mouse hybrids. Somatic Cell Genet 6 (1980) 1-14
39. ATCC. American Type Culture Collection. ATCC. 2004. 2004. Website www.atcc.org. Last accessed 14 Feb 2006.
40. Sharkey F.E., and Fogh J. Metastasis of human tumors in athymic nude mice. Int J Cancer 24 (1979) 733-738
41. KCLB. Korean Cell Line Bank. KCLB. 2005. 2004. Website http://cellbank.snu.ac.kr/ENG/default.htm. Last accessed 14 Feb 2006.
42. Pisani P., Bray F., and Parkin D.M. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97 (2002) 72-81
43. Parkin D.M., Bray F.I., and Devesa S.S. Cancer burden in the year 2000. The global picture. Eur J Cancer 37 Suppl 8 (2001) S4-S66
44. El Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
45. Department of Health and Human Services, Centers for Disease Control and Prevention, National Cancer Institutes. US Cancer Statistics Working Group. United States Cancer Statistics: 2000 Incidence. pp 50-77. 2003. Atlanta, GA.
46. Fong Y., Sun R.L., Jarnagin W., and Blumgart L.H. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 229 (1999) 790-799
47. Hamazoe R., Hirooka Y., Ohtani S., Katoh T., and Kaibara N. Intraoperative microwave tissue coagulation as treatment for patients with nonresectable hepatocellular carcinoma. Cancer 75 (1995) 794-800
48. Fong Y. A promising technique for liver cancer?. Cancer J Sci Am 5 (1999) 339-340
49. Giorgio A., and Ferraioli G. Radiofrequency thermal ablation versus percutaneous ethanol injection for small hepatocellular carcinoma. Radiology 230 (2004) 886-887
50. Zuber-Jerger I., Geissler M., Spangenberg H.C., Mohr L., Weizsacker F., and Blum H.E. Local ablation of malignant lesions of the liver - potential applications and limitations of the different methods. Z Gastroenterol 42 (2004) 31-38
51. Segawa T., Tsuchiya R., Furui J., Izawa K., Tsunoda T., and Kanematsu T. Operative results in 143 patients with hepatocellular carcinoma. World J Surg 17 (1993) 663-667
52. Lau W.Y., Arnold M., Guo S.K., and Li A.K. Microwave tissue coagulator in liver resection for cirrhotic patients. Aust N Z J Surg 62 (1992) 576-581
53. Lencioni R.A., Allgaier H.P., Cioni D., et al. Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228 (2003) 235-240
54. Kramm C.M., Chase M., Herrlinger U., et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 8 (1997) 2057-2068
55. Delman K.A., Zager J.S., Bhargava A., et al. Effect of murine liver cell proliferation on herpes viral behavior: Implications for oncolytic viral therapy. Hepatology 39 (2004) 1525-1532
56. Fong Y., Kemeny N., Jarnagin W., et al. Phase 1 study of a replication-competent herpes simplex oncolytic virus for treatment of hepatic colorectal metastases. Proc Am Soc Clin Oncol 21 (2002) 8a
57. Lin E., and Nemunaitis J. Oncolytic viral therapies. Cancer Gene Ther 11 (2004) 643-664
58. Markert J.M., Medlock M.D., Rabkin S.D., et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 7 (2000) 867-874